Agoracom Blog Home

Posts Tagged ‘COVID-19’

Kontrol $KNR $KNR.ca $KNR.c $KNRLF to provide BioCloud Field Demonstration and Customer application access $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 9:09 AM on Tuesday, February 23rd, 2021
  • On a case-by-case basis and subject to the required customer approval the Company will provide video access and any relevant operating data.
  • “We understand the value and importance of sharing BioCloud units in operation across various customer applications,” says Paul Ghezzi, CEO of Kontrol.

TORONTO, ON / February 23, 2021 / Kontrol Technologies Corp. (CSE:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company“) is pleased to announce that it plans to provide real-time demonstration of BioCloud units in operation in various customer and/or pilot customer (“customer”) applications. On a case-by-case basis and subject to the required customer approval the Company will provide video access and any relevant operating data.

“We understand the value and importance of sharing BioCloud units in operation across various customer applications,” says Paul Ghezzi, CEO of Kontrol. “To the extent that we have customer approval we will also share operating data with respect to specific applications. Where we are unable to provide specific operating access to a customer application, we will seek to aggregate and showcase that data in a manner which meets any privacy constraints.”

The Company will work with its customers to share photos and videos of the BioCloud units in operation and share that content. In certain cases, a customer pilot may be restricted from being shared based on the customer’s requirements for non-disclosure. Over the coming weeks the Company anticipates sharing multiple demonstrations of BioCloud in operation.

Production Improvement

The Company has been working with its contract manufacturing partners to enhance the production design of BioCloud with a specific emphasis on reducing the number of circuit boards. The number of circuit boards has been reduced to 5 starting from an initial prototype design of 11. These improvements are considered part of the normal course of moving from prototype to scale production. The reduction in circuit boards will also provide an opportunity to lower manufacturing costs in the future.

Update to Distribution Model

The Company currently has 11 total distributors and 3 sales referral agreements. The sales referral agreements relate to the China and Middle East markets. The sales referral agreements are non-exclusive in nature. The Company has chosen to limit the number of Canadian non-exclusive distribution agreements, from its original plans, given its view that the Canadian market has sufficient distributors in place. The Company is currently negotiating multiple new potential agreements for the USA and the Middle East on a non-exclusive basis.

Read More: https://agoracom.com/ir/KontrolTechnologies/forums/discussion/topics/755883-kontrol-to-provide-biocloud-field-demonstration-and-customer-application-access/messages/2304893#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Establishes Scientific Advisory Board for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 10:21 AM on Monday, February 22nd, 2021
  • Announce that it has established its previously announced scientific advisory board, (see press release dated January 20th, 2021) to assist the Company to accelerate existing applications and to develop new BioCloud technology applications.
  • “Now more than ever viral detection technology is critical to getting the economy and everyday life back to normal,” says Paul Ghezzi, CEO of Kontrol.

TORONTO, ON / February 22, 2021 / Kontrol Technologies Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company“) is pleased to announce that it has established its previously announced scientific advisory board, (see press release dated January 20th, 2021) to assist the Company to accelerate existing applications and to develop new BioCloud technology applications.

“Now more than ever viral detection technology is critical to getting the economy and everyday life back to normal,” says Paul Ghezzi, CEO of Kontrol. “Vaccines are integral to a broader recovery, however more technology is required for detection and monitoring. We are pleased to be taking a leadership role in this new industry of real-time viral detection infrastructure. Our technology was developed for the current pandemic and the pandemics of the future.”

“We are very pleased to establish a world class advisory board for Kontrol BioCloud,” says Gary Saunders, VP Kontrol. “Our advisory board members are at the top of their field and their counsel will be very important to the future of Kontrol BioCloud and other innovative applications of the technology we may seek to develop.”

Read More: https://agoracom.com/ir/KontrolTechnologies/forums/discussion/topics/755793-kontrol-establishes-scientific-advisory-board-for-biocloud-technology/messages/2304704#message

Ontario Government Invests $2 Million in Kontrol $KNR $KNR.ca $KNR.c $KNRLF #BioCloud COVID-19 Technology $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 10:47 AM on Thursday, February 4th, 2021

Investment to accelerate the production of innovative new technology while creating jobs

  • Ontario government is providing $2 million to CEM Specialties Inc. (“CEMSI“), a London based subsidiary of Kontrol Technologies Corp., through the Ontario Together Fund to help commercialize and accelerate production of Kontrol BioCloudTM, a COVID-19 detector.
  • Kontrol BioCloud (“BioCloudTM“), developed by CEMSI, is a made-in-Ontario real-time COVID-19 detection device that continuously monitors the presence of the SARS-COV-2 virus in the air.

TORONTO, ON / February 4, 2021 / Kontrol Technologies Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company“), is pleased to announce that the Ontario government is providing $2 million to CEM Specialties Inc. (“CEMSI“), a London based subsidiary of Kontrol Technologies Corp., through the Ontario Together Fund to help commercialize and accelerate production of Kontrol BioCloudTM, a COVID-19 detector.

“From day one, Ontario unleashed its innovation and manufacturing might in the fight against COVID-19, with businesses rolling out new innovations and products to help keep the frontlines and the general public safe,” said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. “It’s the creativity and ingenuity of enterprising companies like CEMSI, with its innovative COVID-19 detection technology, that will help Ontario and the rest of the world successfully emerge from this pandemic, while creating hundreds of good jobs for our province’s skilled workers.”

Kontrol BioCloud (“BioCloudTM“), developed by CEMSI, is a made-in-Ontario real-time COVID-19 detection device that continuously monitors the presence of the SARS-COV-2 virus in the air. The technology promotes air circulation, monitors air quality and samples continuously for pathogens like viruses, bacteria and fungi. When the presence of the virus is detected, BioCloud provides an alert in the cloud or over a local intranet. The Company has received all approvals required to commercialize and produce the technology. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

With Ontario’s support, CEMSI plans to increase production capacity to 20,000 units per month. The product will be manufactured in London with more than 85 per cent of its components produced in province. The company anticipates accelerating the production of the BioCloud will create up to 250 direct jobs and up to 750 indirect jobs.

Read More: https://agoracom.com/ir/KontrolTechnologies/forums/discussion/topics/754657-ontario-government-invests-2-million-in-kontrol-biocloud-covid-19-technology/messages/2302021#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Changes Name to “KONTROL TECHNOLOGIES CORP.” and Announces Continuance under the Business Corporations Act (Ontario) $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 8:23 AM on Monday, February 1st, 2021
  • Announced that it has completed its corporate name change
  • The Company’s CSE ticker symbol “KNR”, OTC Markets ticker symbol “KNRLF”, and Frankfurt Stock Exchange ticker symbol “1K8” will remain unchanged.
  • The Company’s common shares are expected to resume trading on the CSE under the name “Kontrol Technologies Corp.” on or about February 5, 2021.

TORONTO, ON / February 1, 2021 / Kontrol Technologies Corp. (formerly Kontrol Energy Corp.) (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol Technologies” or “Kontrol” or “Company“), is pleased to announce that it has completed its corporate name change (the “Name Change“) and continuation out of the Province of British Columbia under the provisions of the Business Corporations Act (British Columbia) into the Province of Ontario under the provisions of the Business Corporations Act (Ontario) (the “Continuance“), as approved by the shareholders of the Company at the Annual General and Special Meeting held on August 28, 2020. Copies of the certificate of continuation and the articles will be filed under the Company’s profile at www.sedar.com and www.thecse.com. There will be no change in the day-to-day business of the Company as a result of the Continuance.

The Company’s CSE ticker symbol “KNR”, OTC Markets ticker symbol “KNRLF”, and Frankfurt Stock Exchange ticker symbol “1K8” will remain unchanged. The Company’s common shares are expected to resume trading on the CSE under the name “Kontrol Technologies Corp.” on or about February 5, 2021. Trading under the name “Kontrol Technologies Corp.” is subject to approval from the Canadian Securities Exchange (CSE) and receipt of new CUSIP and ISIN numbers. The Company will update the market of the effective date of the name change once available.

“The name change to Kontrol Technologies Corp. better reflects our future and our brand,” says Paul Ghezzi, CEO of Kontrol. “We look forward to advancing our energy management, GHG emission and viral detection technologies, which form the foundation of our smart buildings and smart cities solutions.”

Kontrol Energy Group Inc. remains an operating subsidiary of Kontrol Technologies Corp.

Read More: https://agoracom.com/ir/KontrolTechnologies/forums/discussion/topics/754318-kontrol-changes-name-to-kontrol-technologies-corp-and-announces-continuance-under-the-business-corporations-act-ontario/messages/2301342#message

Innocan Pharma $INNO.ca Announces Successful Production of #CBD Loaded Liposomes under Aseptic Conditions $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:57 AM on Friday, January 22nd, 2021
Innocan-Blog
  • Announced today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.
  • This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

Herzliya, Israel and Calgary, Alberta–(January 22, 2021) –  Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC PINK: INNPF) (the “Company” or “Innocan“), is pleased to announce today a successful manufacturing demonstration of liposome platform technology (“LPT“) CBD-loaded Liposomes under aseptic conditions, together with the Hebrew University of Jerusalem.

This is an important milestone in the production process of CBD-loaded Liposomes, as it now permits the demonstration of animal studies and, at a later date, human clinical studies ─ both of which bring the product closer to the marketplace.

This achievement supports studies on small and large animals, examining the therapeutic efficacy of Innocan’s CBD-loaded LPT in relevant diseases. These studies follow the results of previous studies that demonstrated the prolonged release of cannabidiol into the blood of mice and rats for at least three weeks after a single injection.

The previous study, led by Dr. Ahuva Cern, Senior Researcher in the laboratory of Professor Barenholz at the Hebrew University in Jerusalem, found significant amounts of CBD in the blood and muscles of mice up to 21 days after a single intramuscular injection of CBD using the LPT. The same findings were also demonstrated in rats.

Read More: https://agoracom.com/ir/InnocanPharma/forums/discussion/topics/753657-innocan-pharma-announces-successful-production-of-cbd-loaded-liposomes-under-aseptic-conditions/messages/2299445#message

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Advances BioCloud Technology for European Sales and Provides Update $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 7:48 AM on Wednesday, January 20th, 2021
kontrol-logo
  • Announced that it continues to advance the deployment of its BioCloud technology
  • Initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications
  • In the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications
  • “We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

TORONTO, ON / January 20, 2021 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that it continues to advance the deployment of its BioCloud technology.

“We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,” says Paul Ghezzi, CEO. “Through our growing distribution network, we have been presented with numerous potential customers applications. Most recently we have reviewed various applications for professional and amateur sports.”

Non-Disclosure Agreement (NDA)

BioCloud has entered into a Non-Disclosure Agreement, with a leading medical sports authority, to share the full scope of BioCloud’s patents and research. The purpose of the NDA is to advance various potential sport applications. Such applications include, but are not limited to, dressing rooms and training facilities.

BioCloud European Standards

Kontrol has initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications, which is an important prerequisite for European sales. As part of the product requirements for each country within the European Union there may be further standards approval required but these will be dealt with on a case-by-case basis.

Distribution Network

Kontrol has recently added a South Korean firm to its growing distribution network and is in discussion with numerous interested parties.

Viral/Pathogen Advisory Committee

Kontrol is in the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications. Kontrol seeks to establish the committee in February 2021.

Corporate Name Change

Kontrol’s corporate name change to Kontrol Technologies Corp. is anticipated to be completed by the end of January 2021. There has been no specific delay in the process other than the time it takes to complete filings between B.C. and Ontario corporate registries and all of the associated requirements.

About Kontrol BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

Read More: https://agoracom.com/ir/KontrolEnergy/forums/discussion/topics/753445-kontrol-advances-biocloud-technology-for-european-sales-and-provides-update/messages/2299011#message

Innocan Pharma $INNO.ca Successfully Completes Large Scale Production of Exosomes $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 4:15 PM on Thursday, January 14th, 2021
Innocan-Blog
  • Announced the successful completion of a large-scale production of exosomes
  • Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process.
  • Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX.
  • This achievement is expected to pave the way for larger tests and studies.

Herzliya, Israel and Calgary, Alberta–(January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.

Emerging Markets Report: Technology to help get the Pandemic Under Kontrol $KNR $KNR.ca $KNR.c $KNRLF

Posted by AGORACOM-JC at 7:21 AM on Tuesday, January 12th, 2021
kontrol-logo

An Emerging Markets News Commentary

  • According to the The Globe and Mail , “The country, as a whole, and each province is not doing enough to acknowledge aerosol transmission of COVID-19 and promoting the appropriate measures to combat it, such as (improved) ventilation and informing people about the risks of being in indoor spaces with multiple people.”
  • But what if there were a device that could detect the actual presence of COVID-19 in the shared air? What if you could know if your building was safe or not safe in real time?
  • Kontrol Energy Corp ( CSE:KNR ) ( OTCQB:KNRLF ) is a Canadian public company and a leader in smart buildings and cities technology

ORLANDO, Fla., Jan. 12, 2021 — A recent report in Canada’s The Globe and Mail sends a strong signal that it is time for governments and businesses to get smarter and safer amid the danger of the global COVID-19 pandemic. While a sober call-out, the report does display an urgent need for companies like Kontrol Energy Corp ( CSE:KNR ) ( OTCQB:KNRLF ), a Canadian public company and a leader in smart buildings and cities technology.

According to the The Globe and Mail , “The country, as a whole, and each province is not doing enough to acknowledge aerosol transmission of COVID-19 and promoting the appropriate measures to combat it, such as (improved) ventilation and informing people about the risks of being in indoor spaces with multiple people.”

But what if there were a device that could detect the actual presence of COVID-19 in the shared air? What if you could know if your building was safe or not safe in real time?

Read More: https://agoracom.com/ir/KontrolEnergy/forums/discussion/topics/752786-emerging-markets-report-technology-to-help-get-the-pandemic-under-kontrol/messages/2297156#message

VIDEO – Kontrol $KNR $KNR.ca $KNR.c $KNRLF Bullish on #BioCloud as Compliment to Vaccines and HVAC Upgrades $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 6:26 PM on Monday, January 11th, 2021
kontrol-logo

Kontrol Energy (KNR:CSE) (KNRLF:OTCQB) is the Google NEST of smart building technology, with the Blue Chip client base to prove it.  As such, when COVID-19 started shutting down buildings, arenas and complexes, their announcement the Receipt Of Positive Lab Results for Live COVID-19 Testing was taken very seriously by the investment community, with the stock smashing through to all-time highs and consolidating nicely in the $3.00 range as investors prepares for mass commercialization.

Though some impatient “investors” unrealistically demanded immediate and big sales agreements for the BioCloud unit, priced at $US 12,000 EACH $KNR CEO Paul Ghezzi and his team know that real success comes from building a real foundation – and they did that in a mind boggling 5 months.  We’ve been in the smallcap business long enough to know that pulling off the following in 4 months is damn near impossible, until now:

DISTRIBUTION – On December 1, 2020 KNR announced Entering into Exclusive Distribution Agreement with United Safety and Survivability Corporation for BioCloud Technology Distribution in North America, Australia and New Zealand. The exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America , Australia , and New Zealand . The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes. 

In addition, KNR has also entered into two non-exclusive BioCloud distribution agreements covering Ontario and Saskatchewan.

MORE GOVERNMENT FUNDING –  On December 3rd, 2020 the Company announced that it had received an additional $500,000 in research and development funding from the Canadian Federal Government.  This comes after a $50,000 grant earlier this year.  

PATENTS FILED  – On November 30, 2020 KNR announced the filing of 4 patents for the BioCloud technology with 3 patents filed in the USA and 1 patent in Canada .

MANUFACTURING –  KNR has engaged OES Inc. a local design and contract manufacturer in London, Ontario to produce the BioCloud units.  OES Inc. has a long and established history of assisting with the design and manufacturing of complex technology. Initial maximum capacity has been set at 10,000 units per month.

Watch or listen to this powerful interview with Kontrol Energy CEO, Paul Ghezzi.

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Appoints New Director to Its Board $SNE $MSFT $HON $GOOGL $QCOM

Posted by AGORACOM-JC at 8:02 AM on Wednesday, January 6th, 2021
kontrol-logo
  • Announced that Mr. Philip (Zhengquan) Chen has been appointed to its Board of Directors.
  • Mr. Chen is an experienced finance professional and has participated in numerous capital markets transactions in both Canada and the USA. He is also the Managing Partner of Dynaco Capital Inc.

TORONTO, ON / January 6, 2021 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“), a leader in smart buildings and cities through IoT, Cloud and SaaS technology, is pleased to announce that Mr. Philip (Zhengquan) Chen has been appointed to its Board of Directors.

Mr. Chen is an experienced finance professional and has participated in numerous capital markets transactions in both Canada and the USA. He is also the Managing Partner of Dynaco Capital Inc.

“We are very pleased to have Mr. Chen join our Board, as an independent board member, as we continue to work in preparation of an uplisting to senior North American stock exchanges,” says Paul Ghezzi, CEO Kontrol.

Read More: https://agoracom.com/ir/KontrolEnergy/forums/discussion/topics/752409-kontrol-appoints-new-director-to-its-board/messages/2296219#message